Suppr超能文献

全膝关节置换术后维生素 C 需求增加:一项双盲安慰剂对照随机研究。

Vitamin C demand is increased after total knee arthroplasty: a double-blind placebo-controlled-randomized study.

机构信息

Department of Orthopaedic Surgery and Traumatology, Cantonal Hospital, St. Gallen, Rorschacherstreet 95, 9007, St. Gallen, Switzerland.

Department of Medical Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland.

出版信息

Knee Surg Sports Traumatol Arthrosc. 2019 Apr;27(4):1182-1188. doi: 10.1007/s00167-018-5030-3. Epub 2018 Jun 28.

Abstract

PURPOSE

This study was designed to determine whether perioperative supplementation of vitamin C (VC) improves range of motion (ROM) and reduces the risk of arthrofibrosis (AF) following total knee arthroplasty (TKA).

METHODS

Ninety-five patients undergoing TKA were randomized to either oral VC (1000 mg daily) or placebo for 50 days (48 VC group, 47 placebo group). The effect of VC supplementation was tested on ROM, AF, WOMAC, FJS-12, and VC plasma concentrations (VCc). VCc were analyzed in both patient groups before surgery, 4 and 7 days after surgery.

RESULTS

ROM at 1 year was not different between study groups. The prevalence of AF was 5 of 48 (10.4%) in the VC group compared to 11 of 47 (23.4%) in the placebo group (p = 0.09). VCc decreased post-operatively in the placebo group (49-12 µmol/l on day 7, p < 0.001), but not in the VC group (53-57 µmol/l). Patients with a perioperative drop of VCc ≥ 30 µmol/l developed significantly more AF at 1 year compared to patients with a VCc drop of < 30 µmol/l (p = 0.007).

CONCLUSIONS

TKA results in VC depletion. Perioperative VC supplementation prevents VCc drop in most patients undergoing TKA and may lower the incidence of AF. The clinical relevance of this study is that VC supplementation seems to be a cheap and safe adjunct to improve functional outcome after TKA.

LEVEL OF EVIDENCE

I.

TRIAL REGISTRY

The study was registered at the ISRCTN registry with study ID ISRCTN40250576.

摘要

目的

本研究旨在确定围手术期补充维生素 C(VC)是否能改善全膝关节置换术后的关节活动度(ROM)并降低关节纤维强直(AF)的风险。

方法

95 例行 TKA 的患者被随机分为口服 VC(每天 1000mg)或安慰剂组,共 50 天(48 例 VC 组,47 例安慰剂组)。在 ROM、AF、WOMAC、FJS-12 和 VC 血浆浓度(VCc)方面测试了 VC 补充的效果。在手术前、手术后 4 天和 7 天对两组患者的 VCc 进行了分析。

结果

1 年时两组的 ROM 无差异。VC 组中 AF 的发生率为 5/48(10.4%),而安慰剂组为 11/47(23.4%)(p=0.09)。安慰剂组术后 VCc 下降(第 7 天 49-12µmol/l,p<0.001),而 VC 组则没有(53-57µmol/l)。围手术期 VCc 下降≥30µmol/l 的患者在 1 年时发生 AF 的明显多于 VCc 下降<30µmol/l 的患者(p=0.007)。

结论

TKA 导致 VC 耗竭。围手术期 VC 补充可预防大多数接受 TKA 的患者的 VCc 下降,并可能降低 AF 的发生率。本研究的临床意义在于,VC 补充似乎是一种廉价且安全的辅助手段,可改善 TKA 后的功能结局。

证据水平

I。

试验注册

该研究在 ISRCTN 登记处注册,研究 ID 为 ISRCTN40250576。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验